Ligand-directed signaling at the β3-adrenoceptor produced by 3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists

Molecular Pharmacology

Volumn 72, Issue 5, 2007, Pages 1359-1368

  Sato, Masaaki ^a   Horinouchi, Takahiro ^a,b   Hutchinson, Dana S ^a   Evans, Bronwyn A ^a   Summers, Roger J ^a  

^a MONASH UNIVERSITY   (Australia)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2',5' DIDEOXYADENOSINE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR; CYCLIC AMP; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; DIOXOLES; ENZYME INHIBITORS; LIGANDS; MICE; PROPANOLAMINES; PROTEIN-TYROSINE KINASES; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 35548946776     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.035337     Document Type: Article

References (29)

1. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100:11406-11411.
2. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
3. 1- adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138:99-106.
4. 3- adrenergic receptor antagonists. J Pharmacol Exp Ther 290:649-655.
5. Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, Floering LM, Spiegelman BM, and Collins S (2004) p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol 24:3057-3067.
6. 3-adrenergic receptor is required for MAP kinase activation. J Biol Chem 275:38131-38134.
7. Cao W, Medvedev AV, Daniel KW, and Collins S (2001) β-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase. J Biol Chem 276:27077-27082.
8. Clarke WP (2005) What's for lunch at the conformational cafeteria? Mol Pharmacol 67:1819-1821.
9. 3-adrenoceptor antagonist, SR59230A. Eur J Pharmacol 348:223-228.
10. 3-adrenoceptor antagonism by H89. Biochim Biophys Acta 1538:206-217.
11. 2-adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
12. 3 adrenergic receptor: new pharmacological profile and mechanism of activation. Mol Pharmacol 55:255-262.
13. Horinouchi T and Koike K (2001) Agonistic activity of SR59230A at atypical β-adrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol 416:165-168.
14. 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signaling pathways. Br J Pharmacol 135:1903-1914.
15. 3-adrenoceptor revealed by SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4- tetrahydronapth-1-ylamino]-2S-2-propanol oxalate]. J Pharmacol Exp Ther 312:1064-1074.
16. Kenakin TP (2003) The secret lives of GPCRs. Drug Discov Today 8:674.
17. Khaled AR, Moor AN, Li A, Kim K, Ferris DK, Muegge K, Fisher RJ, Fliegel L, and Durum SK (2001) Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol Cell Biol 21:7545-7557.
18. i-mediated in Brown adipocytes. J Biol Chem 275:22670-22677.
19. 3-selective antagonists, aryloxypropanolamino tetralins. Br J Pharmacol 117:435-442.
20. 3-adrenoceptors causes phosphorylation of p38 mitogen-activated protein kinase via a stimulatory G protein-dependent pathway in 3T3-L1 adipocytes. Br J Pharmacol 135:951-960.
21. Penn RB, Parent JL, Pronin AN, Panettieri RA Jr, and Benovic JL (1999) Pharmacological inhibition of protein kinases in intact cells: antagonism of β-adrenergic receptor ligand binding by H-89 reveals limitations of usefulness. J Pharmacol Exp Ther 288:428-437.
22. 3-adrenoceptor associated with differential G protein coupling. J Pharmacol Exp Ther 315:1354-1361.
23. 3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem 274:12017-12022.
24. 3- adrenoceptor constitutes indeed a versatile receptor. Trends Pharmacol Sci 18:52-53.
25. 2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171.
26. Tenhunen O, Rysa J, Ilves M, Soini Y, Ruskoaho H, and Leskinen H (2006a) Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ Res 99(5):485-493.
27. Tenhunen O, Soini Y, Ilves M, Rysa J, Tuukkanen J, Serpi R, Pennanen H, Ruskoaho H, and Leskinen H (2006b) p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. FASEB J 20:1907-1909.
28. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
29. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, et al. (1999) RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 291:680-687.